Astria Therapeutics To Present Initial Navenibart ALPHA-STAR Data At The Upcoming European Academy Of Dermatology And Venereology Congress
Astria Therapeutics To Present Initial Navenibart ALPHA-STAR Data At The Upcoming European Academy Of Dermatology And Venereology Congress
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial navenibart ALPHA-STAR data at the upcoming European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, the Netherlands on September 26, 2024.
專注於開發改變生活的過敏和免疫性疾病療法的生物製藥公司Astria Therapeutics, Inc.（納斯達克股票代碼：ATXS）今天宣佈，它將在即將於2024年9月26日在荷蘭阿姆斯特丹舉行的歐洲皮膚病與性病學會（EADV）大會上公佈navenibart Α-STAR的初步數據。
Raffi Tachdjian, M.D., MPH, Associate Clinical Professor of Medicine and Pediatrics in the Division of Allergy and Clinical Immunology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), will present a poster titled "ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple Doses of STAR-0215 in Patients with Hereditary Angioedema: Initial Safety and Efficacy Outcomes." The poster will be presented in e-poster showcase six on Thursday, September 26 at 4:20pm CEST.
加州大學洛杉磯分校（UCLA）戴維·格芬醫學院過敏與臨床免疫學系醫學和兒科副臨床教授 Raffi Tachdjianwand.D.，MPH，一項針對遺傳性血管性水腫患者單劑量和多劑量 STAR-0215 的臨床副教授 Raffi Tachdjianwand.D.，MPH：初步安全性和有效性結果。”該海報將於歐洲中部夏令時間9月26日星期四下午 4:20 在第六屆電子海報展示會上展出。
